Clinical trials: Acute Gout Flare
Acute Gouty Arthritis, Acute Pain
Treatment of Topical Ketorolac Gel in Acute Gouty Flare
This study will be a phase 1, open-label, bioavailability, safety and PK study of topically applied transcutaneous ketorolac tromethamine gel 12.5% (/w) (NOV-1776) versus intravenous administration of approved ketorolac…
- Conditions
- Acute Gouty Arthritis, Acute Pain, Gout Flare
- Trial name
- NCT06273813
- Testing
- Ketorolac Tromethamine 15 MG/ML, Ketorolac Tromethamine
- Where
- 2 sites in Australia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Novilla Pharmaceuticals
Acute Gouty Arthritis
Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease
The purpose of this study is to confirm the efficacy and safety results obtained in a chronic kidney disease (CKD) subgroup of patients participating in Phase III studies in a larger, independent patient population with difficult…
- Trial name
- NCT01593527
- Testing
- ACZ885, Triamcinelone acetonide
- Sponsor
- Novartis Pharmaceuticals
Infection, Heart Failure
Serum Potassium Prediction Using Machine Learning and Single-lead ECG
This is a retrospective study drawing on data from the Brigham and Women's Hospital Home Hospital Program's Database. Sociodemographic and clinical data from a training cohort were used to train a machine learning algorithm to…
- Conditions
- Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT07493798
- Testing
- Potassium estimation algorithm
- Where
- 2 sites in United States
- Sponsor
- Brigham and Women's Hospital
Gout Flare
Efficacy and Safety of Simiaowan in Prevention of Acute Flares in Chronic Gout Patients Initiating Febuxostat Therapy
The aim of this study is to evaluate the efficacy and safety of simiaowan in prevention of acute flares in chronic gout patients initiating febuxostat therapy.
- Trial name
- NCT04069325
- Testing
- simiaowan, febuxostat
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Gout Arthritis
A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.
The purpose of this study is to determine the efficacy and safety of recombinant anti-interleukin-1β humanized monoclonal antibody injection in Chinese gout participants Initiating Urate-Lowering Treatment.
- Trial name
- NCT06270225
- Testing
- Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg, Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg, Colchicine 0.5 mg
- Where
- China
- Volunteers
- 157 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Gout Flares
A Proof-of-Concept Study of AC-201 to Prevent Gout Flares
Initiation of ULT for gout increases the occurrence of acute gouty arthritis flares due to mobilization of urate from tissue deposits. IL-1β plays a key role in mediating the inflammatory response in gouty arthritis.
- Trial name
- NCT01712204
- Testing
- AC-201, Febuxostat
- Where
- Taiwan
- Volunteers
- 82 people
- Sponsor
- TWi Biotechnology, Inc.
Arthritis, Gouty
Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout
This is an exploratory proof-of-concept study to evaluate the safety and efficacy of canakinumab (ACZ885) for inflammation and pain associated with acute gouty arthritis.
- Trial name
- NCT00663169
- Testing
- canakinumab, dexamethasone
- Where
- 4 sites in United States, Switzerland and 1 more
- Volunteers
- 6 people
- Sponsor
- Novartis
Gouty Arthritis
Long Term Study of Canakinumab (ACZ885) in Patients With Gout
This 24-week open-label extension study is designed to provide additional long-term safety data up to a total of 1-year for patients rolling over from the core study, and to collect further efficacy and tolerability data for all…
- Trial name
- NCT00927810
- Testing
- Canakinumab
- Where
- 45 sites in United States, Argentina and 16 more
- Volunteers
- 341 people
- Sponsor
- Novartis Pharmaceuticals
Acute Gouty Arthritis
Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout
This study is designed to develop our understanding of the efficacy and safety of using lumiracoxib in the treatment of patients with acute gout.
- Trial name
- NCT00170781
- Testing
- Lumiracoxib
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 234 people
- Sponsor
- Novartis
Acute Kidney Injury, Sepsis
Novel Biomarkers for Early Renal Injury in Children With Sepsis
Toxicosis often leads to multiple organ failure (MODS), with the kidney being the primary target organ due to its sensitivity to infection and ischemia.
- Conditions
- Acute Kidney Injury, Sepsis, Gout Flare
- Trial name
- NCT06197828
- Testing
- This study is an observational studie which have no intervention
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Acute Gout, Gout Flare
Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare
To evaluate the safety and efficacy of Genakumab for Injection in patients with gout flare as a first line therapy
- Trial name
- Gensci 048-203 (NCT05936268)
- Testing
- Genakumab for injection, Colchicine
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Gout
Colchicine Or Naproxen Treatment for ACute gouT
Gout is the most common cause of inflamed joints affecting 1.4% of adults in the UK. Most patients are treated entirely in general practice yet primary care management is frequently suboptimal.
- Trial name
- CONTACT (NCT01994226)
- Testing
- Low-dose colchicine, Naproxen 750 mg/250 mg
- Where
- United Kingdom
- Volunteers
- 399 people
- Sponsor
- Keele University
Acute Gout
Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout
The goal of this study is to evaluate the efficacy and safety of Recombinant Human Tumor necrosis Factor-α Receptor Ⅱ Fusion Protein （rhTNFR-Fc）in the treatment of patients with acute Gout.
- Trial name
- NCT05925166
- Testing
- rhTNFR-Fc, methylprednisolone
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Lihua Duan
Gout Flare, Gout Attack
The Effect of Tart Cherry Juice on Risk of Gout Attacks
The purpose of this study is to determine whether consuming tart cherry juice daily for 12 months reduces the risk of gout attacks during this period.
- Trial name
- NCT03621215
- Testing
- Tart cherry juice
- Where
- United Kingdom
- Volunteers
- 38 people
- Sponsor
- Sheffield Hallam University
Acute Gout Flare
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of recombinant Anti-IL-RAP humanised monoclonal antibody injection in healthy Chinese subjects (Part A) and subjects with acute gout flare…
- Trial name
- NCT07295496
- Testing
- IBI3011
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Gout
Does Allopurinol Prolong a Treated, Acute Gout Flare?
This is a double blind placebo controlled study to determine whether starting allopurinol during a treated acute gout attack will have any effect on the duration of the attack.
- Trial name
- NCT01988402
- Testing
- allopurinol
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- 59th Medical Wing
Infection, Heart Failure
Prediction of Patient Deterioration Using Machine Learning
This is a retrospective observational study drawing on data from the Brigham and Women's Home Hospital database. Sociodemographic and clinic data from a training cohort were used to train a machine learning algorithm to predict…
- Conditions
- Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT05045742
- Testing
- Traditional vital sign alarms versus the BioVitals Index vs the National Early Warning Score 2
- Where
- 2 sites in United States
- Volunteers
- 526 people
- Sponsor
- Brigham and Women's Hospital
Infections, Heart Failure
Rural Hospital-Level Care at Home for Acutely Ill Adults
This study examines the implications of providing hospital-level care in rural homes.
- Conditions
- Infections, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT05256303
- Testing
- Home Hospital care, Traditional Hospital care
- Where
- 3 sites in United States, Canada
- Volunteers
- 160 people
- Sponsor
- Brigham and Women's Hospital
Gout, Hyperuricemia
Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients
The aim of this 6-month randomized multi-regional double-blind parallel group placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
- Conditions
- Gout, Hyperuricemia, Gout Flare, Tophi
- Trial name
- EURELIA1 (NCT05586958)
- Testing
- Tigulixostat
- Where
- 52 sites in United States, Georgia and 2 more
- Volunteers
- 354 people
- Sponsor
- LG Chem